Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time-Reference-Cited by-同舟云学术

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

Published:2020-01-28 Issue:2 Volume:9 Page:115-123
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Netterberg Ida¹,Bruno René²,Chen Ya‐Chi³,Winter Helen³,Li Chi‐Chung³,Jin Jin Y.³,Friberg Lena E.¹

Affiliation:

1. Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden

2. Department of Clinical Pharmacology Genentech‐Roche Marseille France

3. Department of Clinical Pharmacology Genentech South San Francisco California USA

Funder

Cancerfonden

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12489

Reference37 articles.

1. US Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER) Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.Guidance for Industry. (2018).

2. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

3. Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer

4. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response

5. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung Cancer;JCO Precision Oncology;2024-02

2. Current Status and Future Directions: The Application of Artificial Intelligence/Machine Learning for Precision Medicine;Clinical Pharmacology & Therapeutics;2024-01-03

3. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model;International Immunopharmacology;2024-01

4. Explainable deep learning for tumor dynamic modeling and overall survival prediction using Neural-ODE;npj Systems Biology and Applications;2023-11-18

5. Pharmacometrics Golems: Exposure‐Response Models in Oncology;Clinical Pharmacology & Therapeutics;2022-03-14